MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:33Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Progestogens]]
			[[Category:Sex hormones]]
			[[Category:Hormone replacement therapy]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #117

2026-05-23T03:46:16Z

parser-claude batch MedTemplate pre-fill, Top 300 #117

New page

{{MedTemplate
| generic = Progesterone (micronized)
| brand = Prometrium (oral), Endometrin (vaginal), Crinone (vaginal gel), Prochieve
| structure =
| classes = [[:Category:Progestogens|Progestogen]], [[:Category:Sex_hormones|Sex hormone]], [[:Category:Hormone_replacement_therapy|Hormone replacement therapy]]
| uses = <vote slug="hrt-endometrial-protection-use">Endometrial protection in estrogen-containing HRT</vote>, <vote slug="amenorrhea-use">Secondary amenorrhea</vote>, <vote slug="art-luteal-support-use">Luteal support in assisted reproduction</vote>, <vote slug="preterm-birth-prevention-use">Preterm birth prevention (vaginal, in selected pregnancies)</vote>
| starting_dose = HRT cyclic: 200 mg PO HS days 1-12 of each month; continuous: 100 mg PO daily; ART luteal support 100 mg vaginal TID or 90 mg gel daily
| preparations = Oral 100, 200 mg capsules (peanut oil; check allergy); 100 mg vaginal insert (Endometrin); 4%, 8% vaginal gel (Crinone); IM 50 mg/mL
| fda_max = Indication-dependent; 200-400 mg/d oral typical
| pill_id =
| routes = Oral, vaginal, intramuscular
| onset = Sedation/dizziness within hours of oral dose; endometrial effects over days
| duration = Oral: 8-12 hours; vaginal: 24+ hours; IM: days
| halflife = ~5-20 hours (oral micronized; highly variable)<ref name="prometrium-label">FDA Prescribing Information, Prometrium (progesterone, USP, micronized), Catalent Pharma, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019781s033lbl.pdf</ref>
| bioavailability = Oral: very low (extensive first-pass); micronization improves uptake somewhat. Vaginal: high local effect with lower systemic levels (first-uterine-pass concentration)<ref name="prometrium-label" />
| pregnancy = Vaginal preparations are used in early pregnancy for luteal support and (in selected high-risk patients) for preterm birth prevention. Bioidentical progesterone has reassuring data in pregnancy compared with synthetic progestins.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="progesterone-mech-claim">Micronized progesterone is the bioidentical form of the endogenous hormone; it binds the progesterone receptor (PR-A and PR-B) to drive secretory transformation of estrogen-primed endometrium and supports the maintenance of early pregnancy, and is the structural template for all synthetic progestins.</vote> Oral progesterone undergoes substantial first-pass to allopregnanolone (a positive allosteric GABA-A modulator), which accounts for the characteristic sedation and dizziness with oral dosing (and the typical HS administration). Vaginal administration provides the "first-uterine-pass effect" — direct uterine delivery with comparatively low systemic levels<ref name="prometrium-label" />.
}}

== References ==
<references />

Progesterone - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #117